Escitalopram
Dysthymic Disorder
Nova Scotia Health AuthoritySmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Dysthymic Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pramine New York State Psychiatric Institute | Phase 4 | BBB |
Fluoxetine New York State Psychiatric Institute | Phase 4 | BB |
DESVENLAFAXINE New York State Psychiatric Institute | Phase 4 | BB |
VENLOR University of Washington | Phase 4 | BB |
Armodafinil Cephalon | Phase 4 | BB |
View all 13 →
Same molecule, other indications
Escitalopram is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →